Myovant Sciences Ltd. (MYOV) |
|
26.98 -0.01 (-0.04%)
|
03-09 16:01 |
|
Open: |
26.99 |
Pre. Close: |
26.99 |
|
High:
|
27 |
Low:
|
26.98 |
|
Volume:
|
2,256,078 |
Market Cap:
|
2,624(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:20:40 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 31.6 One year: 36.91 |
| Support: |
Support1: 26.92  Support2: 26.84 |
| Resistance: |
Resistance1: 27.05 Resistance2: 31.6 |
| Pivot: |
26.95 |
| Moving Average: |
MA(5): 26.97 MA(20): 26.95
MA(100): 26.72 MA(250): 19.2 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 84.2 %D(3): 69 |
| RSI: |
RSI(14): 61  |
| 52-week: |
High: 27.05 Low: 7.67 |
| Average Vol(K): |
3-Month: 1,051 (K) 10-Days: 1,680 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MYOV ] has closed below upper band by 18.8%. Bollinger Bands are 94.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 80 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
27.04 - 27.18 |
27.18 - 27.29 |
|
Low:
|
26.66 - 26.81 |
26.81 - 26.93 |
|
Close:
|
26.77 - 26.99 |
26.99 - 27.18 |
|
Company Description |
|
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd. |
Headline News |
Fri, 29 Sep 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims ... - PR Newswire
Fri, 10 Mar 2023
Sumitovant Biopharma Completes Acquisition of Myovant Sciences - PR Newswire
Thu, 26 Jan 2023
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 - Yahoo Finance
Wed, 16 Nov 2022
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of ... - GlobeNewswire
Sun, 23 Oct 2022
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences ... - PR Newswire
Thu, 13 Oct 2022
Myovant Sciences rejects $2.5bn takeover bid from Sumitomo Pharma - Pharmaceutical Technology
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
97 (M) |
| Shares Float |
51 (M) |
|
% Held by Insiders
|
48.6 (%) |
|
% Held by Institutions
|
56.2 (%) |
|
Shares Short
|
8,390 (K) |
|
Shares Short P.Month
|
6,740 (K) |
Stock Financials |
|
EPS
|
-1.92 |
|
EPS Est Next Qtl
|
-0.44 |
|
EPS Est This Year
|
-1.45 |
|
EPS Est Next Year
|
-1.21 |
|
Book Value (p.s.)
|
-5.75 |
|
Profit Margin (%)
|
-48.5 |
|
Operating Margin (%)
|
-38.8 |
|
Return on Assets (ttm)
|
-18.3 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
84 |
|
Gross Profit (p.s.)
|
0.74 |
|
Sales Per Share
|
3.89 |
|
EBITDA (p.s.)
|
-1.5 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-270 (M) |
|
Levered Free Cash Flow
|
-149 (M) |
Stock Valuations |
|
PE Ratio
|
-14.06 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-4.7 |
|
Price to Sales
|
6.92 |
|
Price to Cash Flow
|
-9.73 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
